gist

(redirected from gists)
Also found in: Dictionary, Medical, Legal, Encyclopedia, Wikipedia.
Related to gists: GitHub
  • noun

Synonyms for gist

Synonyms for gist

Synonyms for gist

the central meaning or theme of a speech or literary work

References in periodicals archive ?
In fact, nuclear palisading and perivascular hyalinization are seen in up to 33% of GISTs.
A total of 946 patients with advanced and/or metastatic KIT-positive GIST received either a 400 or 800 mg dose of Glivec per day (400 mg twice daily).
Grossly, GISTs are usually centered in the bowel wall but may extend to involve either the mucosal or the serosal surfaces.
In addition to leiomyosarcoma, 10% to 47% of GISTs show expression of SMA.
9] Hence, the features of FLSs cannot be specific to GISTs but could be of interest if we consider the causality of FLS collagen fibrils and GISTs or the possibility of GISTs producing such collagen.
The approval for this new indication is based on data from a National Cancer Institute-sponsored Phase III study that showed a dramatic reduction in the return of GIST after surgery in patients treated for about one year with Gleevec versus placebo.
Microscopically, the benign GISTs (leiomyoma) were composed of spindle cells with pale or eosinophilic fibrillar cytoplasm.
Trials have evaluated alternative treatments for imatinib-resistant GIST, whether early or late.
GISTs are the most common malignant form of sarcoma that arise in the gastrointestinal tract, predominantly affecting people between 30 - 60 years of age.
The tumor suppressor protein PTEN was intact (positive expression) in the majority of GISTs, including 88% (15/17) of D-WT and 100% (20/20) of TKI-R GISTs.
The discovery of oncogenic KIT kinase mutations in GISTs and the introduction of kinase inhibitor therapies have led to a rapid evolution in the understanding of these tumors.
After identification of activating mutations in the coding sequence of KIT as the pathogenetic mechanism underlying most GISTs, (2) and the concurrent availability of the ABL/KIT/PDGFR kinase inhibitor imatinib mesylate in early clinical trials for chronic myelogenous leukemia, (3) Joensuu et al (4) demonstrated for the first time the activity of this compound in a solid tumor.
We present a case of recurrent gastrointestinal (GI) bleeding from multiple GISTs in a patient with NF1.
For those patients whose GIST does return, this can be devastating both physically and emotionally, even though Glivec can manage recurring GISTs.